Co-Diagnostics, Inc. (CODX)
| Market Cap | 7.97M -15.2% |
| Revenue (ttm) | 718,166 -79.5% |
| Net Income | -48.50M |
| EPS | -29.82 |
| Shares Out | 3.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75,616 |
| Open | 2.410 |
| Previous Close | 2.280 |
| Day's Range | 2.180 - 2.410 |
| 52-Week Range | 1.260 - 46.500 |
| Beta | 2.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In... [Read more]
Financial Performance
In 2025, Co-Diagnostics's revenue was $622,489, a decrease of -84.10% compared to the previous year's $3.92 million. Losses were -$46.90 million, 24.6% more than in 2024.
Financial StatementsNews
Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform
PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India SALT LAKE CITY, July 22, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on July 21, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics appoints Wes Lindsey as Chief Scientific Officer
Co-Diagnostics (CODX) appointed Wes Lindsey as its new Chief Scientific Officer. Lindsey holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from Georgia State University.
Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer
SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on July 10, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 count...
Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs Analytical data to support concurrent 510(k) ...
Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States
Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -- Co-Diagn...
Co-Diagnostics signs distribution agreement for CO-Dx PCR Pro in Mexico
Co-Diagnostics (CODX) has entered into an exclusive distribution agreement with its partner in Mexico for the Co-Dx PCR point-of-care platform, including the PCR Pro instrument and associated test kit...
Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro ® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2026...
Co-Diagnostics announces continued progress in Ebola PCR development program
Co-Diagnostics (CODX) announced continued progress in its Ebola PCR development program with joint venture CoSara Diagnostics. The program includes development of both a pan-Ebola assay designed to ra...
Co-Diagnostics trading halted, volatility trading pause
09:35 EDT Co-Diagnostics (CODX) trading halted, volatility trading pause
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regions Potential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of-c...
Co-Diagnostics files to sell 4.94M shares of common stock for holders
17:14 EDT Co-Diagnostics (CODX) files to sell 4.94M shares of common stock for holders
Co-Diagnostics Registration statement: Registration filing
Co-Diagnostics filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Co-Diagnostics trading halted, volatility trading pause
09:59 EDT Co-Diagnostics (CODX) trading halted, volatility trading pause
Co-Diagnostics trading resumes
10:04 EDT Co-Diagnostics (CODX) trading resumes
Co-Diagnostics and CoSara Diagnostics advance with ebola PCR development
Co-Diagnostics (CODX) announced that it has advanced the PCR assay development strategy for the Bundibugyo virus, or BDBV, currently causing an outbreak of Ebola disease in the Democratic Republic of…
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally SALT LAKE CITY, May 26, 2026 /PRNewswire/ -- Co-Diagnos...
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics develops ebola assay strategy after recent global outbreak alert
Co-Diagnostics (CODX) has completed the assay development strategy for the Bundibugyo virus currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo and Uganda. On May…
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform Follows outbreak of Ebola and WHO emergency declaration...
Co-Diagnostics reports Q1 EPS ($4.06) vs. ($7.05) last year
Reports Q1 revenue $0.15M vs. $0.05M last year. Cash and cash equivalents totaled $8.2M as of March 31, 2026, vs. $11.9M as of December 31, 2025. “The progress we’ve made…
Co-Diagnostics Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue growth but continued operating losses due to increased R&D and platform investments. Strategic progress includes clinical milestones, local manufacturing in India and Saudi Arabia, and automation initiatives, with additional capital likely needed for commercialization.